Abstract | PURPOSE:
Endoglin, an endothelial cell membrane receptor expressed on angiogenic tumor vessels, is essential for angiogenesis and upregulated in the setting of VEGF inhibition. TRC105 is an anti- endoglin IgG1 monoclonal antibody that potentiates VEGF inhibitors in preclinical models. This study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with bevacizumab. EXPERIMENTAL DESIGN: Patients (n = 38) with advanced solid tumors, Eastern Cooperative Group performance status 0-1, and normal organ function were treated with escalating doses of TRC105 plus bevacizumab until disease progression or unacceptable toxicity using a standard 3 + 3 phase I design. RESULTS: CONCLUSIONS:
|
Authors | Michael S Gordon, Francisco Robert, Daniela Matei, David S Mendelson, Jonathan W Goldman, E Gabriela Chiorean, Robert M Strother, Ben K Seon, William D Figg, Cody J Peer, Delia Alvarez, Bonne J Adams, Charles P Theuer, Lee S Rosen |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 20
Issue 23
Pg. 5918-26
(Dec 01 2014)
ISSN: 1557-3265 [Electronic] United States |
PMID | 25261556
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2014 American Association for Cancer Research. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- carotuximab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, pharmacokinetics)
- Antibodies, Monoclonal, Humanized
(administration & dosage, pharmacokinetics)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bevacizumab
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Neoplasms
(diagnosis, drug therapy, pathology)
- Treatment Outcome
|